How to take Eculizumab

Eculizumab (Eculizumab) can be used to treat paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). Healthcare professionals who prescribe eculizumab must participate in the Soliris REMS program.

1. Recommended dosage:

(1) Paroxysmal nocturnal hemoglobinuria (PNH): For patients 18 years of age and older, eculizumab therapy consists of 600 mg weekly for the first 4 weeks, followed by a fifth dose of 900 mg 1 week later, and 900 mg every 2 weeks thereafter. Administer eculizumab at the recommended dosing schedule time points or within two days of these time points.

(2) Atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG), neuromyelitis optica spectrum disorder (NMOSD): For patients 18 years of age and older, eculizumab therapy consists of 900 mg weekly for the first 4 weeks, followed by a fifth dose of 1,200 mg 1 week later, and 12,000 mg every 2 weeks thereafter. Administer eculizumab at the recommended dosing schedule time points or within two days of these time points.

For aHUS patients <18 years of age, use eculizumab based on body weight: patients ≥40 kg, 900 mg weekly for the first 4 weeks, followed by a fifth dose 1 week later 12,000 mg, then 1,200 mg every 2 weeks thereafter; for patients ≥30kg to <40kg, 600mg weekly for the first 2 weeks, then 900mg for the third dose 1 week later, and 900mg every 2 weeks thereafter; ≥20 For patients from 10kg to <30kg, 600mg per week for the first 2 weeks, then 600mg for the third dose 1 week later, and 600mg every 2 weeks thereafter; for patients from ≥10kg to <20kg, 600mg per week for the first 1 week, Subsequently, the second dose is 300 mg 1 week later, and 300 mg every 2 weeks thereafter; for patients ≥5 kg to <10 kg, the first dose is 300 mg in the first week, followed by the second dose 300 mg 1 week later, and 300 mg every 3 weeks thereafter.

2. Medication management: Eculizumab is administered only as an intravenous infusion, via gravity administration, syringe pump or infusion pump. The eculizumab mixture is infused intravenously for 35 minutes in adult patients and for 1 to 4 hours in pediatric patients. If adverse reactions occur during use, the infusion may be slowed down or stopped at the physician's discretion. If the infusion rate is slowed, the total infusion time for adults should not exceed two hours. After the infusion is completed, monitor the patient for at least one hour for signs or symptoms of infusion-related reactions.

The generic drug Eculizumab has been launched in China and is included in medical insurance. Reimbursement is limited to eligible patients. The specifications areThe price of each box of 300mg (30ml) may be more than 3,000 yuan. It is understood that the price of each box of the original Eculizumab drug sold overseas is more than 6,000 US dollars (the price may fluctuate due to the exchange rate). The ingredients of the original drug sold at home and abroad are basically the same, and the price of the original drug is still relatively expensive. There are currently no generic versions of eculizumab available on the market.